Last reviewed · How we verify
mRNA vaccine booster
At a glance
| Generic name | mRNA vaccine booster |
|---|---|
| Also known as | BNT162b2 |
| Sponsor | Universidad del Desarrollo |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Headache
- Fatigue
- COVID-19
- Injection site pain
- Upper respiratory tract infection
- Injection Site Pain
- Myalgia
- Injection Site Tenderness
- Chills
- Arthralgia
- Malaise
- Muscle Pain
Key clinical trials
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. (PHASE2)
- A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia (PHASE2)
- COVID-19 Reactogenicity (PHASE4)
- Immunosuppression and COVID-19 Boosters (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA vaccine booster CI brief — competitive landscape report
- mRNA vaccine booster updates RSS · CI watch RSS
- Universidad del Desarrollo portfolio CI